🚀 VC round data is live in beta, check it out!
Implanet Valuation Multiples
Discover revenue and EBITDA valuation multiples for Implanet and similar public comparables like Theraclion, Vivos, BrainCool, Myomo and more.
Implanet Overview
About Implanet
Implanet SA designs produce and sell medical implants and devices used in orthopedic surgery. Its products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, and anchors. The company operates in a single segment - the commercialization of orthopedic implants. It derives Majority of its geographical revenue from France.
Founded
2007
HQ
Employees
46
Website
Sectors
Financials (FY)
EV
$39M
Implanet Financials
Implanet reported last fiscal year revenue of $15M and negative EBITDA of ($4M).
In the same fiscal year, Implanet generated $8M in gross profit, ($4M) in EBITDA losses, and had net loss of ($5M).
Implanet P&L
In the most recent fiscal year, Implanet reported revenue of $15M and EBITDA of ($4M).
Implanet expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $15M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $8M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 55% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (30%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (31%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (35%) | XXX | XXX | XXX |
| Net Debt | — | — | $3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Implanet Stock Performance
Implanet has current market cap of $35M, and enterprise value of $39M.
Market Cap Evolution
Implanet's stock price is $0.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39M | $35M | -3.6% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImplanet Valuation Multiples
Implanet trades at 2.6x EV/Revenue multiple, and (8.8x) EV/EBITDA.
Implanet Financial Valuation Multiples
As of April 20, 2026, Implanet has market cap of $35M and EV of $39M.
Equity research analysts estimate Implanet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Implanet has a P/E ratio of (6.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35M | XXX | $35M | XXX | XXX | XXX |
| EV (current) | $39M | XXX | $39M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (8.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (8.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.8x | XXX | XXX | XXX |
| P/E | — | XXX | (6.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Implanet Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Implanet Margins & Growth Rates
Implanet's revenue in the last fiscal year grew by 33%.
Implanet's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Implanet Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 33% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (30%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (16%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 87% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Implanet Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Implanet | XXX | XXX | XXX | XXX | XXX | XXX |
| Theraclion | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivos | XXX | XXX | XXX | XXX | XXX | XXX |
| BrainCool | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| Acarix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Implanet M&A Activity
Implanet acquired XXX companies to date.
Last acquisition by Implanet was on XXXXXXXX, XXXXX. Implanet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Implanet
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialImplanet Investment Activity
Implanet invested in XXX companies to date.
Implanet made its latest investment on XXXXXXXX, XXXXX. Implanet invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Implanet
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Implanet
| When was Implanet founded? | Implanet was founded in 2007. |
| Where is Implanet headquartered? | Implanet is headquartered in France. |
| How many employees does Implanet have? | As of today, Implanet has over 46 employees. |
| Is Implanet publicly listed? | Yes, Implanet is a public company listed on Euronext Paris. |
| What is the stock symbol of Implanet? | Implanet trades under ALIMP ticker. |
| When did Implanet go public? | Implanet went public in 2013. |
| Who are competitors of Implanet? | Implanet main competitors are Theraclion, Vivos, BrainCool, Myomo. |
| What is the current market cap of Implanet? | Implanet's current market cap is $35M. |
| What is the current revenue of Implanet? | Implanet's last fiscal year revenue is $15M. |
| What is the current EV/Revenue multiple of Implanet? | Current revenue multiple of Implanet is 2.6x. |
| Is Implanet profitable? | No, Implanet is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.